About Fibralign

Nanoweave® Technology

Fibralign’s patented Nanoweave® technology provides the means to induce self-assembly of molecular type I collagen to replicate native tissue scaffold outside of the body. This fundamental breakthrough enables medical grade collagen to be precisely printed with nanoscale features that mimic human tissue – to such a degree that the body’s tissue will interact with it naturally and not reject or challenge it as a foreign object.

Fibralign’s core technology provides a versatile platform for tissue engineering and regenerative medicine. BioBridge® is the first product commercialized using the Nanoweave® technology.

The company’s development efforts have built deep expertise and a robust technology toolbox, validated in preclinical studies through collaborations with leading research institutions. This foundation supports a growing pipeline of novel therapies targeting conditions where lymphatic impairment plays a critical role, including neurological disorders, cardiovascular disease, and glaucoma.